Omega‐3 fatty acids for treating residual depressive symptoms in adult patients with bipolar disorder: A systematic review and meta‐analysis of double‐blind randomized, placebo‐controlled trials

Abstract

The results of two previous meta-analyses, which examined whether omega-3 fatty acids (omega-3s), such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), improved residual depressive symptoms (RDSs) for bipolar disorder (BD) patients compared with placebo, were inconsistent (Table S1).^1,2 A study reported that omega-3 was superior to placebo¹; however, another did not.²

Read the full article ›